EDESA BIOTECH, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
EDESA BIOTECH, INC. (EDSA) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $25.29 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-13
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $25.29K.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $50.59K.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $75.88K.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $25.29K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $25.29K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $50.59K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $75.88K 10-Q · filed 2026-02-13 |
| 2025-06-30 | $25.29K 10-Q · filed 2025-08-08 |
| 2025-03-31 | $50.59K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $75.88K 10-Q · filed 2025-02-14 |
| 2024-06-30 | $25.29K 10-Q · filed 2024-08-09 |
| 2024-03-31 | $50.59K 10-Q · filed 2024-05-10 |
| 2023-12-31 | $75.88K 10-Q · filed 2024-02-09 |
| 2023-06-30 | $25.29K 10-Q · filed 2023-08-09 |
| 2023-03-31 | $50.59K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |